Publications

Detailed Information

Activation of toll-like receptors 2, 3 or 5 induces matrix metalloproteinase-1 and-9 expression with the involvement of MAPKs and NF-κB in human epidermal keratinocytes

DC Field Value Language
dc.contributor.authorLee, Youngae-
dc.contributor.authorKim, Hyunjung-
dc.contributor.authorKim, Sangmin-
dc.contributor.authorKim, Kyu Han-
dc.contributor.authorChung, Jin Ho-
dc.date.accessioned2012-07-04T00:25:02Z-
dc.date.available2012-07-04T00:25:02Z-
dc.date.issued2010-08-
dc.identifier.citationEXPERIMENTAL DERMATOLOGY; Vol.19(8); E44-E49ko_KR
dc.identifier.issn0906-6705-
dc.identifier.urihttps://hdl.handle.net/10371/78337-
dc.description.abstractToll-like receptors (TLRs) on epidermal keratinocytes are the first line of defense against microbe invasion, and matrix metalloproteases (MMPs) regulate inflammation, cell migration and wound healing. In this study, we demonstrate that the mRNA and protein expressions of MMP-1 and MMP-9 in human epidermal keratinocytes are induced by ligands for TLR2, TLR3 and TLR5 [Pam3CSK4, Poly(I:C) and flagellin, respectively] in a dose-dependent manner. We also found that the ligands for TLR2, TLR3 and TLR5 activate the MAP kinases, JNK and p38 MAPK, but not ERK1/2. Furthermore, treatment with the ligands for TLR2, TLR3 and TLR5 also induced the degradation of I kappa B-alpha and activated the nuclear translocation of NF-kappa B. MMP-1 induction by the ligands for TLR2, TLR3 and TLR5 was inhibited by pretreatment with BAY11-7082 (NF-kappa B inhibitor) or SP600125 (JNK inhibitor), whereas MMP-9 expression was inhibited by pretreatment with BAY11-7082, SP600125 or SB203580. These findings demonstrate that the activation of TLR2, TLR3 or TLR5 induces the expression of MMP-1 and MMP-9 in human epidermal keratinocytes. In addition, NF-kappa B or JNK mediated the MMP-1 expression induced by TLR2, TLR3 and TLR5, whereas NF-kappa B, JNK or p38 MAPK mediated the MMP-9 expression induced by TLR2, TLR3 and TLR5.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELLko_KR
dc.subjectkeratinocytesko_KR
dc.subjecttoll-like receptorsko_KR
dc.subjectmatrix metalloproteinase-1ko_KR
dc.subjectmatrix metalloproteinase-9ko_KR
dc.titleActivation of toll-like receptors 2, 3 or 5 induces matrix metalloproteinase-1 and-9 expression with the involvement of MAPKs and NF-κB in human epidermal keratinocytesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이영애-
dc.contributor.AlternativeAuthor김현중-
dc.contributor.AlternativeAuthor김상민-
dc.contributor.AlternativeAuthor김규한-
dc.contributor.AlternativeAuthor정진호-
dc.identifier.doi10.1111/j.1600-0625.2009.00963.x-
dc.citation.journaltitleEXPERIMENTAL DERMATOLOGY-
dc.description.citedreferenceLee YM, 2008, EXP DERMATOL, V17, P864, DOI 10.1111/j.1600-0625.2008.00738.x-
dc.description.citedreferenceLiang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992-
dc.description.citedreferenceLim EJ, 2007, EXP MOL MED, V39, P239-
dc.description.citedreferenceLebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530-
dc.description.citedreferenceLee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847-
dc.description.citedreferenceKawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850-
dc.description.citedreferenceKrueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200-
dc.description.citedreferenceO`Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012-
dc.description.citedreferenceWest AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827-
dc.description.citedreferenceTanaka K, 2005, J PHARMACOL EXP THER, V315, P624, DOI 10.1124/jpet.105.088674-
dc.description.citedreferenceLu YB, 2005, J IMMUNOL, V175, P5423-
dc.description.citedreferenceBorregaard N, 2005, J LEUKOCYTE BIOL, V77, P439, DOI 10.1189/jlb.0704381-
dc.description.citedreferenceKida Y, 2005, CYTOKINE, V29, P159, DOI 10.1016/j.cyto.2004.10.009-
dc.description.citedreferenceRITTER M, 2005, J INFLAMM-LOND, V2, P16-
dc.description.citedreferenceAkira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391-
dc.description.citedreferenceHogan RJ, 2004, INFECT IMMUN, V72, P1843, DOI 10.1128/IAI.72.4.1843-1855.2004-
dc.description.citedreferenceJiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101-
dc.description.citedreferenceMcMillan SJ, 2004, J IMMUNOL, V172, P2586-
dc.description.citedreferenceMempel M, 2003, J INVEST DERMATOL, V121, P1389-
dc.description.citedreferenceYamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986-
dc.description.citedreferencede Lara LGV, 2003, AM J PHYSIOL-LUNG C, V285, pL899, DOI 10.1152/ajplung.00082.2003-
dc.description.citedreferenceYamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262-
dc.description.citedreferenceBaker BS, 2003, BRIT J DERMATOL, V148, P670-
dc.description.citedreferenceEndo H, 2003, ARCH DERMATOL RES, V294, P552, DOI 10.1007/s00403-002-0364-5-
dc.description.citedreferenceTakeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126-
dc.description.citedreferenceKawai K, 2002, J DERMATOL SCI, V30, P185-
dc.description.citedreferenceEsteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200-
dc.description.citedreferenceSong PI, 2002, J INVEST DERMATOL, V119, P424-
dc.description.citedreferenceRatzinger G, 2002, J IMMUNOL, V168, P4361-
dc.description.citedreferenceLee CG, 2001, J EXP MED, V194, P809-
dc.description.citedreferenceWestermarck J, 1998, MATRIX BIOL, V17, P547-
dc.description.citedreferenceKahari VM, 1997, EXP DERMATOL, V6, P199-
dc.description.citedreferencePilcher BK, 1997, J CELL BIOL, V137, P1445-
dc.description.citedreferenceSAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190-
dc.description.tc8-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share